Results

Table (1): Comparison between pre treatment and post treatment laboratory investigations in interferon group.

Treatments	Mean*	Std. Deviation	Т	p
pre	14.04	0.779	12 10	< 0.001
post	11.26	0.561	12.10	0.001
pre	5373.60	821.462	13 90	< 0.001
post	3556.00	621.208	13.70	< 0.001
pre	194640.00	27717.143	13 10	< 0.001
post	141200.00	19487.175	13.10	< 0.001
pre	51.24	10.674	9 90	< 0.001
post	22.04	5.898	7.70	< 0.001
pre	46.88	8.177	11 50	< 0.001
post	21.04	4.774	11.50	< 0.001
pre	584560.00	552852.307	5 30	< 0.001
post	0.00	.000	3.30	V.001
	pre post	pre 14.04 post 11.26 pre 5373.60 post 3556.00 pre 194640.00 post 141200.00 pre 51.24 post 22.04 pre 46.88 post 21.04 pre 584560.00	Treatments Mean* Deviation pre 14.04 0.779 post 11.26 0.561 pre 5373.60 821.462 post 3556.00 621.208 pre 194640.00 27717.143 post 141200.00 19487.175 pre 51.24 10.674 post 22.04 5.898 pre 46.88 8.177 post 21.04 4.774 pre 584560.00 552852.307	Treatments Mean* Deviation T pre 14.04 0.779 12.10 post 11.26 0.561 12.10 pre 5373.60 821.462 13.90 post 3556.00 621.208 13.90 pre 194640.00 27717.143 13.10 post 141200.00 19487.175 13.10 pre 51.24 10.674 9.90 post 22.04 5.898 8.177 post 21.04 4.774 11.50 pre 584560.00 552852.307 5.30

*mean values of N=25

P < 0.001

There was statistical comparison between different laboratory values in interferon group before and after treatment and this was statistically significant in all different laboratory results.

Table (2): Comparison between pretreatment and post treatment fibroscan results in interferon group.

					Fibro	oscar	ı pret	reati	ment		
		F	71	F	F2 F3		F4		Total		
		No.	No. % No.			No.	%	No.	%	No.	%
Fibroscan	F0	0	0%	3	12%	5	20%	0	.0%	8	32.0%
post	F1	0	.0%	3	12%	2	8%	0	.0%	5	20.0%
treatment	F2	0	.0%	2	8%	0	.0%	4	16.0%	6	24.0%
	F4	0	.0%	0	.0%	0	.0%	6	24.0%	6	24.0%
	Total	0	0%	8	32%	7	28%	10	40.0%	25	100.0%

$$X^2 = 25.2$$
 $p < 0.01$

There was statistical comparison between fibroscan results before and after treatment in interferon group and this was statistically significant.

Table (3): Comparison between pretreatment and posttreatment laboratory investigations in silymarin group.

		Mean*	Std. Deviation	T	P
Hb	pre	14.08	0.773	2.4	> 0.05
110	post	13.20	0.740	2.1	<i>></i> 0.03
WBC	pre	5322.00	754.139	0.2	> 0.05
WBC	post	5373.60	821.462	0.2	2 0.03
Platelets	pre	194640.00	27717.143	0.4	> 0.05
1 laterets	post	197200.00	25967.929	0.1	2 0.03
AST	pre	22.04	5.898	2.1	> 0.05
7101	post	20.07	5.003	2.1	2 0.03
ALT	pre	21.04	4.774	2.2	> 0.05
1121	post	19.06	4.345	2.2	2 0.02
PCR	pre	584560.00	552852.307	2.01	> 0.05
1010	post	813000.00	694209.082	2.01	7 0.03

*mean values of N=25

P > 0.05

There was statistical comparison between different laboratory values in silymarin group before and after treatment and this was statistically non significant.

Table (4): Comparison between pretreatment and posttreatment fibroscan results in silymarin group.

				fibro	oscan p	retrea	atment		
		I	F2	I	F3	I	74	Total	
		No.	%	No.	%	No.	%	No.	%
	F1	7	28.0%	1	4.0%	1	4.0%	9	36.0%
Fibroscan	F2	1	4.0%	2	8.0%	2	8.0%	5	20.0%
post treatment	F3	4	16.0%	1	4.0%	3	12.0%	8	32.0%
r	F4	1	4.0%	1	4.0%	1	4.0%	3	12.0%
	Total	13	52.0%	5	20.0%	7	28.0%	25	100.0%

$$X^2 = 5.7$$
 $p > 0.05$

There was statistical comparison between fibroscan results in silymarin group before and after treatment and this was statistically non significant.

Table (5): Comparison between pretreatment and posttreatment laboratory investigations in captopril group.

		Mean*	Std. Deviation	T	P
Hb	pre	12.05	0.773	2.1	> 0.05
	post	12.70	0.740	2.1	7 0.02
WBC	pre	5172.00	754.139	0.18	> 0.05
, , DC	post	5553.60	821.462	0.10	7 0.02
Platlets	pre	200123.00	27717.143	0.5	> 0.05
	post	193452.00	25967.929	0.0	7 0.02
AST	pre	29.08	6.002	2.31	> 0.05
	post	33.01	5.993	2.61	7 0.02
ALT	pre	28.04	4.943	1.9	> 0.05
1121	post	30.06	4.676	1.5	7 0.02
PCR	pre	699360.00	582771.602	1.1	> 0.05
2 021	post	813000.00	694209.082		. 0.00

*mean values of N=25

P> 0.05

There was statistical comparison between different laboratory results in captopril group before and after treatment and this was statistically non significant.

Table (6): Comparison between pretreatment and posttreatment fibroscan results in captopril group.

				fibro	oscan p	retre	atment			
		I	F 2	1	F 3]	F 4	Total		
		No.	%	No.	%	No.	%	No.	%	
	F2	6	24.0%	3	12.0%	3	12.0%	12	48.0%	
Fibroscan	F3	6	24.0%	3	12.0%	3	12.0%	12	48.0%	
posttreatment	F4	0	.0%	0	.0%	1	4.0%	1	4.0%	
	Total	12	48.0%	6	24.0%	7	28.0%	25	100.0%	

$$X^2 = 2.7$$
 $p > 0.05$

There was statistical comparison between fibroscan results in captopril group before and after treatment and this was statistically non significant.

Table (7): Comparison between pretreatment and posttreatment laboratory investigations in pentoxiphylline group.

		Mean*	Std. Deviation	t	P
Hb	pre	11.09	0.699	2.7	> 0.05
	post	13.70	0.920	2.7	7 0.03
WBC	pre	5127.00	768.422	0.3	> 0.05
WBC	post	5373.60	831.882	0.5	7 0.03
Platelets	pre	163523.00	22439.825	0.3	> 0.05
	post	187356.00	19967.326	0.5	7 0.05
AST	pre	31.09	6.753	2.23	> 0.05
	post	30.23	6.639	2.25	7 0.05
ALT	pre	37.12	7.004	2.4	> 0.05
	post	33.03	6.993	2	7 0.05
PCR	pre	834520.00	564232.056	1.3	> 0.05
	post	900210.00	598723.002	1.3	7 0.03

*mean values of N=25

P> 0.05

There was statistical comparison between different laboratory results in pentoxiphylline group before and after treatment and this was statistically non significant.

Table (8): Comparison between pretreatment and posttreatment fibroscan results in pentoxiphylline group.

				fibro	oscan p	retrea	atment		
		I	F2	2 F3			F4	Total	
		No.	%	No.	%	No.	%	No.	%
Fibroscan	F2	7	28.0%	3	12.0%	2	8.0%	12	48.0%
posttreatment	F3	3	12.0%	2	24.0%	2	8.0%	7	28.0%
	F4	2	8.0%	1	4.0%	3	12.0%	6	24.0%
	Total	12	48.0%	6	24.0%	7	28.0%	25	100.0%

 $X^2 = 2.4$ p > 0.05

There was statistical comparison between fibroscan results before and after treatment in pentoxiphylline group and this was statistically non significant.

Table (9): Comparison between biopsy and fibro sacn before treatment.

			Biopsy(Metavir)											
		I	F0 F1				F2 F3		F4			Total		
		No.	%	No.	%	No.	%	No.	%	No.	%		No.	%
Fibroscan	F0	0	0%	0	0%	0	0%	0	0%	0	0%		0	0%
pretreatmen	F2	0	0%	23	23%	15	15%	3	3%	0	0%		41	41%
t	F3	0	0%	5	5%	19	19%	2	2%	2	2%		28	23%
	F4	0	0%	0	0%	3	3%	25	25%	3	3%		31	31%
	Total	0	0%	28	28%	37	37%	30	30%	5	5%		100	100%

$$X^2 = 141.6$$
 p < 0.001

There was statistical comparison between liver biopsy results and fibroscan results before treatment and this was statistically significant

Table (10): Statistical analysis for APRI score in Interferon group.

		N	Mean	Std. Deviation	t	р
APRI	pre	25	0.6728	0.22643	5.4	< 0.001
	post	25	0.3920	0.08031	5.1	0.001

There was statistical analysis for APRI score in interferon group before and after treatment and this was statistically significant.

Table (11): Statistical analysis for APRI score in silymarin group.

		N	Mean	Std. Deviation	t	р
APRI	Pre	25	0.2372	0.11349	1.6	> 0.05
	post	25	0.2804	0.05054	1.0	7 0.03

There was statistical analysis for APRI score in silymarin group before and after treatment and this was statistically non significant.

Table (12): Statistical analysis for APRI score in Captopril group.

		N	Mean	Std. Deviation	t	р
APRI	Pre	25	0.2354	o.14245	1.9	> 0.05
	post	25	0.2788	0.05442	1.7	7 0.00

There was statistical analysis for APRI score in captopril group before and after treatment and this was statistically non significant.

Table (13): Statistical analysis for APRI score in pentoxiphylline group.

		N	Mean	Std. Deviation	t	P
APRI	Pre	25	0.2240	0.12325	2.4	> 0.05
	post	25	0.2920	0.05220		

There was statistical analysis for APRI score in pentoxiphylline group before and after treatment and this was statistically non significant.

Table (14): correlation between APRI, fibroscan, biopsy and PCR pretreatment in four groups:

	APRI		
	r	р	
Fibroscan	0.016	0.878	
biopsy	0.069	0.493	
PCR pre	0.012	0.909	

This table shows no significant stastistical correlation between APRI ,fibroscan, biopsy&PCR in the four groups pretreatment.

Table (15): correlation between APRI and fibroscan posttreatment:

	Apri post		
	r	р	
Fibro scan post	-0.021	0.835	

This table shows no significant stastistical correlation between APRI &fibroscan in the four groups posttreatment.

Figure (1): shows the comparison between haemoglobin values before & after treatment in interferon group:




Figure (2): shows the comparison between tranaminases levels before & after treatment in interferon group:




Figure (3): shows the comparison between WBCs levels before &after treatment in interferon group:




Figure (4): shows the comparison between PCR&platlets values before & after treatment in interferon group:




Figure (5): shows the comparison between fibroscan results before &after treatment in interferon group:




Figure (6): shows the comparison between fibroscan results before &after treatment in silymarin group:




Figure (7): shows the comparison between fibroscan results before &after treatment in captopril group:






Figure (8): shows the comparison between fibroscan results before &after treatment in pentoxiphylline group:




Figure(9): correlation between APRI & fibroscan pretreatment in four groups:




This figure shows no significant stastistical correlation between APRI &fibroscan, in the four groups pretreatment.

 $\it Figure(10):$ correlation between APRI & biopsy pretreatment in four groups:




This figure shows no significant stastistical correlation between APRI &biopsy in the four groups pretreatment.

Figure(11): correlation between APRI & PCR pretreatment in four groups:



This figure shows no significant stastistical correlation between APRI &PCR in the four groups pretreatment.

 $\it Figure(12):$ correlation between APRI & fibroscan postreatment in four groups:



This figure shows no significant stastistical correlation between APRI &fibroscan, in the four groups posttreatment.